- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Adaptimmune and Cryoport Collaboration Optimizes Supply Operations
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients,and Cryoport, Inc., a temperature-controlled logistics solutions company serving the life sciences industry, announced a 3-year agreement to ensure safe and fully monitored transport of Adaptimmune’s cell therapies.
This agreement with Cryoport will contribute to optimizing manufacturing and supply operations and other solutions, including investment in the latest systems and technology, digitization of the supply chain information, and improved communications with patients and healthcare professionals.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
